Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

Recruiting now

Conditions studied: Severe Hemophilia A, Severe Hemophilia A With Inhibitor, Severe Hemophilia A Without Inhibitor

In brief

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.

Key facts

Study ID

NCT05802836

Run by

Christoph Königs

People needed

100

Starts

2023-04-26

Expected to finish

2029-12-01

Last updated by the study team

2023-07-10

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Severe congenital hemophilia A (CHA)
• Treatment with emicizumab irrespective of any other treatment
• Informed consent

You may not qualify if…

• No therapy with emicizumab
• Immunosuppressive therapy
• HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl

Where it is running

• University Hospital Frankfurt, Goethe University — Frankfurt am Main, Hesse, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.